文献速递前列腺癌

低危前列腺癌主动监测与根治性前列腺切除术的健康相关生活质量:HAROW前瞻性观察研究

Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW - Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting).
PubMed 文献 · BJU Int · 2018-04-20

HAROW前瞻性观察研究比较低危局限性前列腺癌主动监测(AS)与根治性前列腺切除术(RP)患者的健康相关生活质量(HRQOL)。纳入961例(RP 556例,AS 405例),随访3.5年(中位2年)。控制年龄、合并症和伴侣状态后,AS组在整体HRQOL及角色、情感、社会功能方面有显著但非临床相关的优势;部分量表RP组初始略低,1-2年内恢复至AS水平。

要点

  • 低危前列腺癌AS与RP的HRQOL差异显著但未达临床意义。
  • AS组整体HRQOL及角色、情感、社会功能优于RP组。
  • RP组部分HRQOL量表初始略低,1-2年内恢复至AS水平。

核心结论

  • 在观察性设计中,低危前列腺癌AS患者诊断后1-2年内多数HRQOL方面优于RP,但差异无临床意义。
  • AS患者HRQOL至少不低于RP患者,应纳入低危局限性前列腺癌治疗决策咨询。

研究设计与样本

  • HAROW为前瞻性观察研究,收集新诊断局限性前列腺癌真实世界不同治疗选择的数据。
  • 纳入961例患者(RP 556例,AS 405例),随访3.5年(中位2年),每6个月收集临床数据与HRQOL。
  • 采用纵向多水平分析,控制年龄、合并症和伴侣状态。

主要发现

  • 控制年龄、合并症和伴侣状态后,AS组在整体HRQOL及角色、情感、社会功能方面有显著但非临床相关的优势。
  • 部分HRQOL量表RP组初始略低,1-2年内恢复至AS水平。

临床怎么用

  • 为低危局限性前列腺癌患者咨询时,应告知AS在HRQOL方面至少不劣于RP。
  • HRQOL是前列腺癌治疗决策与咨询的重要方面。

局限性

  • 观察性设计,差异未达临床意义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare health-related quality of life (HRQOL) between patients with localised prostate cancer in an active surveillance (AS) group and a radical prostatectomy (RP) group, as evidence shows that both groups have similar oncological outcomes. Thus, comparative findings on the patients' HRQOL are becoming even more important to allow for informed treatment decision-making. PATIENTS AND METHODS: The Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting (HAROW) study is a prospective, observational study designed to collect data for different treatment options for newly diagnosed patients with localised prostate cancer under real-life conditions. At 6-month intervals, clinical data (D'Amico risk categories, Charlson Comorbidity Index) and HRQOL (European Organisation for Research and Treatment of Cancer quality of life questionnaire 30-item core questionnaire) were collected. Data were analysed by longitudinal multilevel analysis for patients with localised prostate cancer under AS and RP. RESULTS: Data from 961 patients (556 RP, 405 AS) were considered. The follow-up was 3.5 years (median 2 years). The results reveal significant, but not clinically relevant advantages for patients with low-risk prostate cancer managed with AS in contrast to RP concerning global HRQOL as well as role, emotional and social functioning over time, after controlling for age, comorbidities, and partnership status. In some, but not all HRQOL scales, RP patients start with a slightly lower HRQOL and recover up to the level of AS patients within 1-2 years after diagnosis. CONCLUSION: HRQOL is an important aspect in the decision-making and advising process for patients with prostate cancer. In many aspects of HRQOL, AS is associated with more favourable outcomes than RP within the first 1-2 years after diagnosis in our observational design, although the differences were not clinically significant. The result that HRQOL in AS patients is at least as high as in RP patients should be considered when advising patients about the different treatment options for low-risk localised prostate cancer.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Ansmann L, Winter N, Ernstmann N, et al. Health-related quality of life in active surveillance and radical prostatectomy for low-risk prostate cancer: a prospective observational study (HAROW - Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting). BJU Int. 2018. PMID: 29603553. doi:10.1111/bju.14215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。